Sector News

Merck’s Mammen joins Johnson & Johnson to head R&D

June 9, 2017
Life sciences

Mathai Mammen, M.D., Ph.D. is leaving Merck after a little more than a year at the company to take up a position at Johnson & Johnson. The Theravance Biopharma co-founder is set to takeover from William Hait, M.D., Ph.D. as global head of R&D, freeing his predecessor to start a new role overseeing J&J’s prolific partnering operation.

Mammen will join J&J later this month and transition into his new post over the rest of the year. The formal handover is due to take place on January 1. After that, Mammen will serve as global head of R&D at J&J’s Janssen drug development arm. And Hait will start in a newly-created post that gives him oversight of the biotech incubators and network of global partnerships built up by Johnson & Johnson Innovation.

The reshuffle tasks Mammen with continuing Hait’s work to turn J&J into one of the more effective Big Pharma R&D shops. Mammen and the pipeline he oversees will need to keep up this level of performance if J&J is to hit its recently-set targets for new approvals and sales growth.

Hait is leaving Mammen with a pipeline he recently called “one of the most robust and sustainable … in the industry.” And in his new position he will continue to play a role in ensuring the pipeline is stocked with promising prospects. Hait’s new title of global head, J&J external innovation gives him responsibility for the company’s JJDC VC wing, JLABS startup incubators and the innovation centers it has set up in Boston, MA, Menlo Park, CA, London, United Kingdom and Shanghai, China.

These initiatives have enabled J&J to establish relationships with—and keep tabs on the progress of—a large number of young companies.

Appointing Hait to oversee the growing operation reiterates the unit’s importance to J&J. It is now 10 years since Hait left academia to join J&J. When Hait arrived at J&J to head up hematology and oncology R&D, the company was in the middle of consolidating the disparate teams working across its many units in those therapeutic areas. Hait oversaw that work and a period in which J&J established itself as a company to watch in oncology through drugs such as Darzalex.

Mammen’s exit deprives Merck of a SVP it only recently lured away from Theravance. Mammen left Theravance in March 2016 to take up a position at Merck that gave him a leading role in its research in key therapeutic areas, including cardiovascular and metabolic disease, immunology, oncology and immuno-oncology.

By Nick Paul Taylor

Source: Fierce Biotech

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).